1. Home
  2. NKTX vs HEQ Comparison

NKTX vs HEQ Comparison

Compare NKTX & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTX
  • HEQ
  • Stock Information
  • Founded
  • NKTX 2015
  • HEQ 2011
  • Country
  • NKTX United States
  • HEQ United States
  • Employees
  • NKTX N/A
  • HEQ N/A
  • Industry
  • NKTX Biotechnology: Pharmaceutical Preparations
  • HEQ Investment Managers
  • Sector
  • NKTX Health Care
  • HEQ Finance
  • Exchange
  • NKTX Nasdaq
  • HEQ Nasdaq
  • Market Cap
  • NKTX 131.3M
  • HEQ 118.9M
  • IPO Year
  • NKTX 2020
  • HEQ N/A
  • Fundamental
  • Price
  • NKTX $1.97
  • HEQ $10.35
  • Analyst Decision
  • NKTX Strong Buy
  • HEQ
  • Analyst Count
  • NKTX 6
  • HEQ 0
  • Target Price
  • NKTX $15.00
  • HEQ N/A
  • AVG Volume (30 Days)
  • NKTX 675.7K
  • HEQ 43.1K
  • Earning Date
  • NKTX 05-20-2025
  • HEQ 01-01-0001
  • Dividend Yield
  • NKTX N/A
  • HEQ 9.78%
  • EPS Growth
  • NKTX N/A
  • HEQ N/A
  • EPS
  • NKTX N/A
  • HEQ N/A
  • Revenue
  • NKTX N/A
  • HEQ N/A
  • Revenue This Year
  • NKTX N/A
  • HEQ N/A
  • Revenue Next Year
  • NKTX N/A
  • HEQ N/A
  • P/E Ratio
  • NKTX N/A
  • HEQ N/A
  • Revenue Growth
  • NKTX N/A
  • HEQ N/A
  • 52 Week Low
  • NKTX $1.31
  • HEQ $9.08
  • 52 Week High
  • NKTX $8.23
  • HEQ $11.84
  • Technical
  • Relative Strength Index (RSI)
  • NKTX 53.68
  • HEQ 59.74
  • Support Level
  • NKTX $1.81
  • HEQ $10.17
  • Resistance Level
  • NKTX $2.16
  • HEQ $10.39
  • Average True Range (ATR)
  • NKTX 0.16
  • HEQ 0.15
  • MACD
  • NKTX -0.01
  • HEQ 0.04
  • Stochastic Oscillator
  • NKTX 38.32
  • HEQ 80.33

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: